Dr. Christopher McGowan, MD, an obesity medicine specialist at True You Weight Loss, says the decision to drink on Ozempic is ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...